Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted to Altitude Lab, the Salt Lake City biotech accelerator formed by Recursion Pharmaceuticals.
The NIH’s SEED office formed to help startups leverage government’s funding programs. Chris Sasiela, director of the SEED office, discussed these programs during the MedCity News INVEST Conference in Chicago.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Questions about whether acetaminophen use during pregnancy can lead children to develop neurological problems have sparked scientific inquiry and litigation. Lawsuits are continuing, but a new National Institutes of Health-sponsored study has results that show no causal link between acetaminophen and neurodevelopmental disorders.
Long Covid continues to afflict patients and mystify clinicians. The National Institutes of Health is trying to identify potential treatments and it is launching a series of clinical trials that will assess a wide range of therapeutic interventions.
Marburg virus has no FDA-approved vaccines or therapies, but a vaccine candidate from the National Institutes of Health now has encouraging results from a U.S. clinical trial. Next steps include tests in more countries including Ghana, where a Marburg outbreak was declared last summer.
Johnson & Johnson reported results from a mid-stage study in southern Africa showing just 25% efficacy for its HIV vaccine. J&J developed the HIV vaccine with the same technology used in its successful Ebola and Covid-19 vaccines.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
Antibody therapies from Brii Biosciences and Vir Biotechnology failed to show sufficient efficacy to advance to the next stage of an NIH-sponsored Covid-19 clinical trial. Apellis Pharmaceuticals and Durect also stopped work on experimental Covid treatments.
The agency's Covid-19 Treatment Guidelines Panel stated there was insufficient evidence for or against the treatment and pointed out that in certain groups, such as intubated patients, no benefit in seven-day overall survival was observed.
The New York Times reported that the FDA was prepared to issue an emergency use authorization for the treatment last week, but NIH Director Francis Collins and NIAID Director Anthony Fauci intervened, arguing that data were too weak.
The NIAID create the Covid-19 Prevention Trials Network by combining four existing ones, primarily focused on HIV and AIDS, which will continue that work in addition to their new focus on Covid-19.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
A preprint retrospective analysis among 368 patients hospitalized with Covid-19 in the VA system found no benefit and a higher degree of death from hydroxychloroquine. A panel of experts also recommended against using the drug with azithromycin outside of trials due to potential toxicity.
Our weekly cartoon focuses on the National Institutes of Health.
It's likely that many drugs Americans take for granted wouldn't exist today if not for the NIH-funded basic research that enabled their discovery and development. Fortunately, generous funding for the NIH has long enjoyed bipartisan support in Congress.
The partnership will have a particular focus on therapies to treat sickle cell disease and HIV, with each party committing $100 million to the effort.
The partnership builds on an existing relationship between All of Us and Color, which was chosen as one of three genome centers that are responsible for actual genotyping of patient samples.